Conavi Medical Provides Shareholder Update and 2025 Outlook

- U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early 2026
- Evolving medical guidelines position next-generation Novasight system as new imaging standard in interventional cardiology
- Multiple non-dilutive opportunities being pursued to fund growth

Read more at globenewswire.com